SEGMENT INFORMATION (Tables)

6 Months Ended

Jun. 30, 2022

Segment Reporting [Abstract]

Schedule of segment revenues and profit

Segment revenues and profits were as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
(in millions)	2022		2021		2022		2021
Revenues:
Salix	$	501	$	516	$	965	$	988
International	233		313		477		619
Diversified Products	235		264		484		560
Solta Medical	57		73		129		145
Bausch + Lomb	941		934		1,830		1,815
	$	1,967	$	2,100	$	3,885	$	4,127
Segment profits:
Salix	$	354	$	370	$	676	$	697
International	66		103		157		212
Diversified Products	141		162		299		362
Solta Medical	20		39		55		80
Bausch + Lomb	208		213		414		452
	789		887		1,601		1,803
Corporate	(202)		(199)		(396)		(380)
Amortization of intangible assets	(302)		(360)		(612)		(717)
Goodwill impairments	(83)		—		(83)		(469)
Asset impairments, including loss on assets held for sale	(6)		(47)		(14)		(195)
Restructuring, integration, separation and IPO costs	(35)		(9)		(48)		(21)
Other income (expense), net	—		(542)		(2)		(512)
Operating income (loss)	161		(270)		446		(491)
Interest income	3		2		5		4
Interest expense	(410)		(364)		(772)		(732)
Gain (loss) on extinguishment of debt	113		(45)		113		(50)
Foreign exchange and other	4		7		(3)		8
Loss before income taxes	$	(129)	$	(670)	$	(211)	$	(1,261)

Schedule of revenues by segment and product category

Revenues by segment and product category were as follows:

(in millions)	Salix		International		Diversified Products		Solta Medical		Bausch + Lomb		Total
	Three Months Ended June 30, 2022
Pharmaceuticals	$	501	$	69	$	197	$	—	$	117	$	884
Devices	—		—		—		57		392		449
OTC	—		35		1		—		364		400
Branded and Other Generics	—		122		31		—		61		214
Other revenues	—		7		6		—		7		20
	$	501	$	233	$	235	$	57	$	941	$	1,967
	Three Months Ended June 30, 2021
Pharmaceuticals	$	514	$	67	$	223	$	—	$	138	$	942
Devices	—		—		—		73		397		470
OTC	—		32		2		—		325		359
Branded and Other Generics	—		206		31		—		68		305
Other revenues	2		8		8		—		6		24
	$	516	$	313	$	264	$	73	$	934	$	2,100
	Six Months Ended June 30, 2022
Pharmaceuticals	$	965	$	134	$	402	$	—	$	227	$	1,728
Devices	—		—		—		129		778		907
OTC	—		73		3		—		699		775
Branded and Other Generics	—		255		67		—		113		435
Other revenues	—		15		12				13		40
	$	965	$	477	$	484	$	129	$	1,830	$	3,885
	Six Months Ended June 30, 2021
Pharmaceuticals	$	984	$	126	$	465	$	—	$	259	$	1,834
Devices	—		—		—		145		779		924
OTC	—		57		4		—		645		706
Branded and Other Generics	—		418		78		—		119		615
Other revenues	4		18		13		—		13		48
	$	988	$	619	$	560	$	145	$	1,815	$	4,127

Schedule of revenue attributed to a geographic region

Revenues are attributed to a geographic region based on the location of the customer and were as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
(in millions)	2022		2021		2022		2021
U.S. and Puerto Rico	$	1,190	$	1,216	$	2,305	$	2,378
China	74		119		177		229
Canada	88		87		166		163
Poland	63		71		139		133
Mexico	69		56		130		125
France	58		56		115		110
Japan	50		55		101		115
Germany	35		28		80		70
United Kingdom	29		27		57		52
Russia	38		33		63		64
Spain	23		23		44		42
Italy	23		21		43		38
South Korea	20		20		39		40
Other	207		288		426		568
	$	1,967	$	2,100	$	3,885	$	4,127

Schedule of customers that accounted for 10% or more of total revenue

Customers that accounted for 10% or more of total revenues were as follows:

	Six Months Ended June 30,
	2022	2021
AmerisourceBergen Corporation	16%	17%
McKesson Corporation (including McKesson Specialty)	13%	16%
Cardinal Health, Inc.	11%	12%